Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at firstname.lastname@example.org
Depression History Shows No Impact on Efficacy, Safety of Solriamfetol in Treating Obstructive Sleep Apnea, NarcolepsyMarch 24th 2023
Results of solriamfetol were similar when outcomes were examined in subgroups of concomitant antidepressant use, regardless of depression history, indicating that antidepressants did not affect the efficacy of the drug.
Myasthenia Agent Zilucoplan Continues to Show Positive Efficacy in Long-Term ExtensionMarch 23rd 2023
In participants who received placebo during the parent studies, rapid improvements were observed as early as week 1 after switching to zilucoplan, and continued through week 12 of the extension period.
NeuroVoices: Emma Ciafaloni, MD, on Mounting Progress in the Neuromuscular Field, Duchenne Muscular DystrophyMarch 22nd 2023
The professor of neurology and pediatrics at University of Rochester Medical Center shared her thoughts on the 2023 MDA Clinical and Scientific Conference, and the progress made in the treatment of neuromuscular disorders.
Applying Artificial Intelligence to Monitor Multiple Sclerosis Disease ProgressionMarch 15th 2023
Michael Dwyer, PhD, director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center, provided insight on how artificial intelligence techniques may be used to monitor disease progression in multiple sclerosis.
NeuroVoices: Justin Sporrer, MD, on Improvements and Benefits to High Intensity Focused Ultrasound in Essential TremorMarch 15th 2023
The director of functional neurosurgery at Baptist Health Miami Neuroscience Institute provided perspective on the growth of high intensity focused ultrasound and the lessons learned when treating essential tremor.
P-Tau217 Continues to Show Benefit as Predictor of Cognitive Decline in Preclinical Alzheimer DiseaseMarch 14th 2023
Plasma P-tau217 was associated with cognitive decline across several cognitive tests in 2 different cohorts and with conversion to AD dementia in the large-scale, longitudinal BioFINDER-1 cohort.
Cognitive and Functional Differences Identified in Parkinson Disease Prior to DiagnosisMarch 13th 2023
Findings showed that global cognition declines in the prediagnostic period in men but not women with incident Parkinson disease, further indicating cognitive heterogeneity in the prodromal period by sex.
NeuroVoices: Michael Dwyer, PhD, on Appropriately Incorporating Artificial Intelligence, ChatGPT into Multiple Sclerosis CareMarch 8th 2023
The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided perspective on the sudden explosion of artificial intelligence, and how it can be applied to MS care.
Health-Related Quality of Life Improvements Seen in Myasthenia Gravis With EfgartigimodMarch 7th 2023
Efgartigimod resulted in rapid impact on health-related quality of life, with improvements that were consistent across multiple measures and were similar for the effect seen across 2 treatment cycles.